NEUROPLASTICITY IN THE NIGROSTRIATAL SYSTEM OF MPTP-TREATED MICE AT THE PRESYMPTOMATIC AND EARLY SYMPTOMATIC STAGES OF PARKINSONISM
|
|
- Leslie Allen
- 5 years ago
- Views:
Transcription
1 NEUROPLASTICITY IN E NIGROSTRIATAL SYSTEM OF MPTP-TREATED MICE AT E PRESYMPTOMATIC AND EARLY SYMPTOMATIC STAGES OF PARKINSONISM Michael V. Ugrumov Institute of Developmental Biology RAS, Moscow, Russia Russian Academy of Sciences
2 Brain plasticity Ernesto Lugaro ( ) V.M. Bekhterev ( ) The Italian psychiatrist E. Lugaro had introduced the term plasticity into the neurosciences considering that throughout life the anatomo-functional relations between neurons can be changed in an adaptive fashion to enable psychic maturation, learning, and even functional recovery after brain damage. the function of the damaged brain areas is restored due to the undamaged areas. This is accounted for by the reorganization of the interneuronal relations under the information, coming from the target organs. Berlucchi G. 22. J. History Neurosciences, 11,
3 Neuroplasticity in the nigrostriatal system of MPTP-treated mice at the presymptomatic and symptomatic s of parkinsonism Introduction. New insight into the pathogenesis of Parkinson s disease; Dopamine turnover in the nigrostriatal system of MPTP-treated mice at modeling Parkinson s disease at the preclinical and early clinical s with focus on neuroplasticity; Dopamine production by non-dopaminergic expressing individual enzymes of dopamine synthesis as a mechanism of neuroplasticity under a failure of dopaminergic neurons; Conclusions.
4 Bezard and Gross, Prog. Neurobiol. 55, ; Trends Neurosci. 26, ;. Ugrumov, M.V., 28. In: Handbook of Neurochemistry and Molecular Neurobiology. Neurotransmitter Systems, Springer, Heidelberg, pp New insight into the pathogenesis of Parkinson s disease %, % Dopamine in the striatum Dopamine loss Compensatory processes Threshold loss of dopamine Onset of the disease First symptoms Age (years) Pathogenesis: Neurodegeneration; Prion-like propagation; Neuroplasticity; Inflammation Unspecific mechanisms providing neuroprotection: Stimulation of secretion of the growth factors; Activation of the antioxidant systems. Specific mechanisms serving to maintain neurotransmission: Stimulation of neurotransmitter secretion; A reduction of the enzymatic degradation of neurotransmitters; Increase of the sensitivity of the target neurons.
5 Neuroplasticity in the nigrostriatal system of MPTP-treated mice at the presymptomatic and symptomatic s of parkinsonism Introduction. New insight into the pathogenesis of Parkinson s disease; Dopamine turnover in the nigrostriatal system of MPTP-treated mice at modeling Parkinson s disease at the preclinical and early clinical s with focus on neuroplasticity; Dopamine production by non-dopaminergic expressing individual enzymes of dopamine synthesis as a mechanism of neuroplasticity under a failure of dopaminergic neurons; Conclusions.
6 Dopamine content / number of neurons (% of control) Dopamine concentration / number of axons (% of control) Neurotoxic (MPTP) models of Parkinson s disease in mice: Preclinical and early clinical s % 1 Dopamine Striatum Axon 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, pretoxin) (glial cells) 1-methyl-4-pyridine (MPP +, toxin) Axons Clinical Preclinical Injections of MPTP: 1, 2 or 4 times at the individual dose of 12 mg/kg with 2-hours intervals between the injections. Decapitation: 2 weeks after the treatment Striatum Dopaminergic neurons Dopamine-sensitive neurons Substantia nigra Ugrumov M. et al. (211) Neuroscience 181, ; Kozina et al. (214) J Neurol. Sci. 34: % х12 2х12 4х12 N injections x 12 mg/kg MPTP Substantia nigra Cell bodies Dopamine Clinical Preclinical 1х12 2х12 4х12 N injections x 12 mg/kg MPTP Cell body
7 MPTP models in mice of PD at the preclinical and early clinical s: Prospect of the use Evaluation of the molecular mechanisms of neurodegeneration in the central and peripheral nervous system; Evaluation of the mechanisms of neuroplasticity in the central and peripheral nervous system; Search for mechanisms triggering a transition from preclinical to clinical ; Search for peripheral biomarkers for the development of preclinical diagnostics of Parkinson s disease; Development of the provocation test for the diagnostics of Parkinson s disease at the preclinical ; Development of preventive therapy in Parkinson s disease: to slow down neurodegeneration; to control and improve neuroplasticity; to deactivate triggers of motor disorders. Ugrumov (29) J Chem Neuroanat. 38, ; Ugrumov.(211) Neuroscience 181, ; Kozina et al. (214) J Neurol Sci. 34,198-27; Ugrumov (213) Adv Pharmacol. 68:37-91.
8 Nigrostriatal system in MPTP-treated mice: Evaluation of functional activity Substantia nigra Indicators of functional activity: Gene expression, synthesis and activity of tyrosine hydroxylase; Spontaneous and stimulated release of dopamine; Dopamine uptake; Content and turnover of dopamine; Dopamine synthesis by non-dopaminergic neurons; Gene expression and activity of MAO A and B; Gene expression of D2 receptors. The data obtained for the striatum and substantia nigra as a whole were adjusted to individual nigral cell bodies and striatal axons Cell body Axon Striatum
9 Functional activity of the nigrostriatal system in MPTP-treated mice at the presymptomatic and symptomatic s of parkinsonism Conclusions Compensatory processes: An increase of gene expression and activity of tyrosine hydroxylase (), An increase of dopamine (DA) release and turnover, A decrease of MAO B activity. Non-expected results: Regulations of transcription, translation and enzymatic activity of are different; An increase of activity despite and increase of D2 gene expression. Triggers of motor disorders: A decrease of DA stimulated release, An increase of DA uptake, An increase of MAO A activity Object Parameter Tyrosine hydroxylase mrna Tyrosine hydroxylase protein Tyrosine hydroxylase activity Dopamine content Dopamine release spontaneus / stimulated Dopamine uptake Dopamine turnover Neuron Cell body Presympt vs. control Axon Presympt vs. control _ / / Neuron Cell body Presympt vs. sympt. Axon Presympt vs. sympt. D2 receptor mrna / _ / Increase; Decrease; No change; _ No data Ugrumov et al. (211) Neuroscience 181, ; Kozina Ugrumov (214) J Neurol Sci, 34:
10 Neuroplasticity in the nigrostriatal system of MPTP-treated mice at the presymptomatic and symptomatic s of parkinsonism Introduction. New insight into the pathogenesis of Parkinson s disease; Dopamine turnover in the nigrostriatal system of MPTP-treated mice at modeling Parkinson s disease at the preclinical and early clinical s with focus on neuroplasticity; Dopamine production by non-dopaminergic expressing individual enzymes of dopamine synthesis as a mechanism of neuroplasticity under a failure of dopaminergic neurons; Conclusions.
11 Neurons partly expressing dopaminergic phenotype Dopaminergic neurons Striatum Hypothalamus Substantia nigra Pituitary Principal characteristics Non-dopaminergic neurons partly expressing dopaminergic phenotype Two enzymes of dopamine synthesis Dopamine membrane transporter Vesicular membrane transporter, type 2 Individual enzymes of dopamine synthesis No dopamine membrane transporter No vesicular membrane transporter, type 2 Meister B., Hökfelt T. (Sweden), Steinbusch H.W.M. (the Netherlands), Skagerberg G., Lindvall O., Geffard M. (France), Joh T., Cuello A.C., Goldstein M. (1988) Do tyrosine hydroxylase-immunoreactive neurons in the ventro-lateral arcuate nucleus produce dopamine or only L-DOPA? J. Chemical Neuroanat. 1, Hoffman, B.J., Hansson, S.R., Mezey, E., Palkovits, M. (1998). Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front. Neuroendocrinol. 19,
12 Striatum Arcuate nucleus Arcuate nucleus III ventricle Median eminence & (Ikemoto et al., 1997; Cossette et al., 25), aromatic L-amino acid decarboxylase; DAT, dopamine transporter;, tyrosine hydroxylase. Bienzymatic neuron Monoenzymatic neuron Monoenzymatic neuron
13 Dopamine (ng/sample) Dopamine (ng/sample) Dopamine in tissue (pg/mg) Dopamine release (pg/ml) Dopamine in cells (pg/dish) Dopamine release (pg/ml) Cooperative synthesis of dopamine by non-dopaminergic neurons in the arcuate nucleus in rat fetuses ТH 8% 19% ТH+ 1% Arcuate n. 21st embryonic day, ex vivo 3 mm KCl 6 mm KCl th embryonic day, culture 3 mm KCl 6 mm KCl L-Tyrosine Tyrosine hydroxylase Dopaminergic neurons < 1% Tyrosine hydroxylase & aromatic L-amino acid decarboxylase Non-dopaminergic neurons > 99% Dopamine Dopamine synthesis Aromatic L-amino acid decarboxylase.6 Arcuate n..5 STATIC INCUBATION Тyr (-) Тyr (+) Substantia nigra L-DOPA L-Tyrosine Melnikova, Ugrumov (1999) Neuroscience 89, ; Ugrumov et al. (24) Neuroscience 124,
14 Prolactin in plasma (ng/ml) Dopamine (ng / mg tiss) Number of neurons / section Dopamine synthesis by non-dopaminergic neurons as a compensatory mechanism under a failure of tuberoinfundibular dopaminergic neurons Arcuate nucleus ТH & 6-OHDA ТH& ТH& Control 6-OHDA III ventricle & 1 Median eminence Control 6-OHDA 5 6-OHDA.2.1 Norm 14 Ershov, Ugrumov et al., 25, J. Сhem. Neuroanat. 3, 27-33; Ugrumov, 28. In: Handbook of Neurochemistry and Molecular Neurobiology. Neurotransmitter Systems, Springer, Heidelberg, pp Days 14th day 45th day, aromatic L-amino acid decarboxylase; 6-OHDA, 6-hydroxydopamine;, tyrosine hydroxylase
15 Ugrumov, 28. In: Handbook of Neurochemistry and Molecular Neurobiology. Neurotransmitter Systems, Springer, Heidelberg, pp ; Ugrumov M., 213. Adv.Pharmacol. 68, Neurons expressing enzymes of dopamine synthesis in the striatum of rats at 6-OHDA-induced degeneration of nigral dopaminergic neurons 6-hydroxydopamine (6-OHDA) Striatum Substantia nigra Tyrosine hydroxylase Striatum, 6-OHDA Tyrosine hydroxylase Substantia nigra Striatum Tyrosine hydroxylase () Tyrosine hydroxylase Aromatic L-amino acid decarboxylase () Aromatic L-amino acid decarboxylase Control Striatum 6-OHDA 6-OHDA 6-OHDA (Lopez-Real et al., 23)
16 mrna content / striatum, % of control Nigrostriatal system in MPTP-treated mice: Neurons expressing individual enzymes of dopamine synthesis in the striatum Control Preclinical Clinical Fractions of mono- and bienzymatic nerve fibers In the striatum Tyrosine hydroxylase () + 24% 22% 34% 24% 29% 52% 24% 43% 47% Aromatic L-amino acid decarboxylase () & Control gene expression Conclusion: Degeneration of dopaminergic neurons is followed by an increase of the number of monoenzymatic fibers and an appearance of the neurons expressing tyrosine hydroxylase in the striatum Preclinical Preclinical Clinical Clinical
17 Cooperative synthesis of dopamine in the striatum of normal and parkinsonian mice Synthesis of dopamine (DA) in DA-ergic (bienzymatic) neurons L-tyrosine L-DOPA Cooperative synthesis of DA in nonda-ergic (monoenzymatic) neurons dopamine Design of the experiment Flow incubation of the striatal slices for 2 hours: Incubation with L-leucine Striatum Incubation without L-leucine L-DOPA LAT1 tyrosine hydroxylase, aromatic L-amino acid decarboxylase, LAT1 large neutral amino acid transporter. Collection of incubation medium and perfused slices High-performance liquid chromatography with electrochemical detection (HPLC-ED) L-leucine is a competitive inhibitor of LAT1 transporter, preventing L-DOPA uptake. Slices of substantia nigra, containing only bienzymatic neurons served as an additional control. pmol Total dopamine content in the striatum (slices) and medium following flow incubation without L-leucine with L-leucine % 2 1 A decrease of total dopamine content in the striatum (slices) and medium after the incubation with L-leucine 21% 3% 51% pmol 1 5 Total content of dopamine in substantia nigra (slices) and medium after flow incubation without L-leucine with L-leucine Control Preclinical Clinical NaCl 1x12 4x12 Control Preclinical Clinical NaCl 1x12 4x12 NaCl Control Clinical 4x12
18 Pathways for cooperative synthesis of dopamine Dopamine is produced by non-dopaminergic neurons expressing individual complementary enzymes of its synthesis in cooperation; L-Tyrosine Cooperative synthesis of dopamine is a compensatory reaction under a failure of dopaminergic neurons, mostly in neurodegenerative diseases Dopaminergic neuron L-DOPA Dopamine L-Tyrosine L-DOPA Dopamine L-DOPA transporter L-DOPA & TryH& L-tyrosine Non-dopaminergic neurons L-DOPA Dopamine Dopamine Dopamine, aromatic L-amino acid decarboxylase;, tyrosine hydroxylase; TryH, tryptophan hydroxylase Ugrumov, (28) Handbook of Neurochemistry and Molecular Neurobiology (A. Lajtha, ed.) Neurotransmitter Systems (E.S. Vizi, ed.), Springer, pp ; Ugrumov (29) J Chem Neuroanat. 38, ; Ugrumov (213) Adv.Pharmacol. 68,
19 Neuroplasticity in the nigrostriatal system of MPTP-treated mice at the presymptomatic and symptomatic s of parkinsonism Introduction. New insight into the pathogenesis of Parkinson s disease; Dopamine turnover in the nigrostriatal system of MPTP-treated mice at modeling Parkinson s disease at the preclinical and early clinical s with focus on neuroplasticity; Dopamine production by non-dopaminergic expressing individual enzymes of dopamine synthesis as a mechanism of neuroplasticity under a failure of dopaminergic neurons; Conclusions.
20 Conclusions Experimental models of Parkinson s disease at the preclinical and early clinical (PD) were developed using MPTP-treated mice; A model of PD at the early clinical strongly reproduces the pathogenesis in patients regarding gene expression of α-synuclein and major proteins involved in neurotransmission; Despite a certain degradation of dopaminergic system at the model of PD at the preclinical, motor disorders are prevented due to compensatory processes an increase of the gene expression and activity of tyrosine hydroxylase, an increase of dopamine (DA) release and a decrease of MAO B activity; Dopamine in the striatum is produced besides dopaminergic neurons by non-dopaminergic neurons expressing individual enzymes that is among most efficient mechanisms of neuroplasticity at PD; A transition of the presymptomatic to the symptomatic, manifested by the onset of motor disorders is provoked by a decrease of DA stimulated release and an increase of DA uptake and MAO A activity.
21 ACKNOWLEDGMENTS Laboratory of Neural and Neuroendocrine Regulations, Institute of Developmental Biology RAS, Moscow, Russia Thanks for your attention A. Sapronova (PhD, senior researcher), E. Volina (PhD, senior researcher) T. Pronina (PhD, senior researcher) E. Kozina (PhD, researcher) N. Bondarenko (PhD, researcher) G. Khakimova (PhD, researcher) L. Dilmuchametova (PhD, researcher) A. Kolacheva (PhD student) Y. Zubova (PhD student) A. Kim (PhD student) A. Kurina (PhD student) E. Mingazov (PhD student) V. Safandeev (PhD student) A. Murtazina (PhD student) Michael V. UGRUMOV Institute of Developmental Biology RAS, Moscow, Russia S. Surkov (Researcher) V. Kirillova (technician)
DEVELOPING BRAIN AS AN ENDOCRINE ORGAN : A PARADOXIСAL REALITY
2nd International Conference on Endocrinology October 2-22, 214, Chicago, USA DEVELOPING BRAIN AS AN ENDOCRINE ORGAN : A PARADOXIСAL REALITY M.V. Ugrumov Institute of Developmental Biology RAS, Moscow
More informationNeuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide
Neuroprotection in preclinical models of Parkinson disease by the NAPVSIPQ peptide Bruce H. Morimoto, Ph.D. Executive Director, Applied Translational Medicine Microtubules Microtubules essential for neuronal
More informationNeurotransmitters acting on G-protein coupled receptors
Neurotransmitters acting on G-protein coupled receptors Part 1: Dopamine and Norepinephrine BIOGENIC AMINES Monoamines Diamine Overview of Neurotransmitters and Their Receptors Criteria for defining a
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationThe Opportunity: Parkinson s disease, RLS, ADHD, and disease modification YKP10461
The Opportunity: Parkinson s disease, RLS, ADHD, and disease modification YKP10461 1 TABLE OF CONTENTS Profile Summary Mechanism of Action Clinical Study Results Pharmacologic Profile Safety and Toxicity
More informationThe role of pramipexole in a severe Parkinson s disease model in mice
Therapeutic Advances in Neurological Disorders Original Research The role of pramipexole in a severe Parkinson s disease model in mice Seham Gad ElHak, Abdel Aziz Ghanem, Hasan Abdelghaffar, Sahar ElDakroury,
More informationAnalysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease
Oxidative Stress laboratory Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease By Dr. Soliman Khatib Senior lecturer,
More informationNeurotransmitter Systems III Neurochemistry. Reading: BCP Chapter 6
Neurotransmitter Systems III Neurochemistry Reading: BCP Chapter 6 Neurotransmitter Systems Normal function of the human brain requires an orderly set of chemical reactions. Some of the most important
More informationModeling Parkinson s disease: systems to test gene-environment interactions
Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)
More informationParkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.
Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -
More informationUSING LUHMES CELLS AS A MODEL SYSTEM TO STUDY DOPAMINERGIC NEURON CELL BIOLOGY. Tigwa H. Davis, Ph.D. Senior Scientist October 16, 2014
USING LUHMES CELLS AS A MODEL SYSTEM TO STUDY DOPAMINERGIC NEURON CELL BIOLOGY Tigwa H. Davis, Ph.D. Senior Scientist October 16, 2014 About ATCC Founded in 1925, ATCC is a non-profit organization with
More informationPERSPECTIVE. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Deniz Kirik, Biljana Georgievska & Anders Björklund
Localized striatal delivery of GDNF as a treatment for Parkinson disease Deniz Kirik, Biljana Georgievska & Anders Björklund Ten years ago, a glial cell line derived neurotrophic factor (GDNF) that has
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationImpact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson s Disease
Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson s Disease FABIO G. TEIXEIRA,MIGUEL M.CARVALHO KRISHNA M. PANCHALINGAM ANA J.RODRIGUES
More informationGene Therapy (2003) 10, & 2003 Nature Publishing Group All rights reserved /03 $
(2003) 10, 1721 1727 & 2003 Nature Publishing Group All rights reserved 0969-7128/03 $25.00 www.nature.com/gt REVIEW Gene therapy progress and prospects: Parkinson s disease EA Burton 1, JC Glorioso 2
More informationAdvanced Neurotransmitters & Neuroglia
Advanced Neurotransmitters & Neuroglia Otsuka Pharmaceutical Development & Commercialization, Inc. 2017 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC. February
More informationGBME graduate course. Chapter 43. The Basal Ganglia
GBME graduate course Chapter 43. The Basal Ganglia Basal ganglia in history Parkinson s disease Huntington s disease Parkinson s disease 1817 Parkinson's disease (PD) is a degenerative disorder of the
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationThe Role of DOPAL in Parkinson s Disease. Karenee Demery. Copyright May, 2015, Karenee Demery and Koni Stone
The Role of DOPAL in Parkinson s Disease Karenee Demery Copyright May, 2015, Karenee Demery and Koni Stone Parkinson s disease is an incurable, neurodegenerative disease. The cause is still not fully understood.
More informationDamage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.
Lecture 20 - Basal Ganglia Basal Ganglia (Nolte 5 th Ed pp 464) Damage to the basal ganglia produces involuntary movements. Although the basal ganglia do not influence LMN directly (to cause this involuntary
More informationMOVEMENT OUTLINE. The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement
MOVEMENT 2 Dr. Steinmetz 3 OUTLINE The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement Parkinson s Disease Huntington s Disease 1 4 TYPES
More informationNeurotransmitter Systems I Identification and Distribution. Reading: BCP Chapter 6
Neurotransmitter Systems I Identification and Distribution Reading: BCP Chapter 6 Neurotransmitter Systems Normal function of the human brain requires an orderly set of chemical reactions. Some of the
More informationThis is a free sample of content from Parkinson's Disease. Click here for more information or to buy the book.
A AADC. See Aromatic amino acid decarboxylase AAV. See Adeno-associated virus Acetylcholine (ACh), functional imaging, 174 175 ACh. See Acetylcholine Adaptive immune system central nervous system, 381
More informationNIH Public Access Author Manuscript Parkinsonism Relat Disord. Author manuscript; available in PMC 2009 January 1.
NIH Public Access Author Manuscript Published in final edited form as: Parkinsonism Relat Disord. 2008 ; 14(Suppl 2): S84 S87. doi:10.1016/j.parkreldis.2008.04.004. Strengths and Limitations of Genetic
More informationBee venom acupuncture in different neurological illness and its immune modulation ACKNOWLEDGMENTS
Bee venom acupuncture in different neurological illness and its immune modulation ACKNOWLEDGMENTS MONA MOSTAFA FARID 1 Introduction 2 Bee venom have been widely used in Oriental medicine to relieve pain
More informationCheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy
Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:
More informationPETER PAZMANY CATHOLIC UNIVERSITY Consortium members SEMMELWEIS UNIVERSITY, DIALOG CAMPUS PUBLISHER
PETER PAZMANY CATHOLIC UNIVERSITY SEMMELWEIS UNIVERSITY Development of Complex Curricula for Molecular Bionics and Infobionics Programs within a consortial* framework** Consortium leader PETER PAZMANY
More informationBasal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota
Basal Ganglia Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Graduate School Discussion Wednesday, Nov 1, 11:00am MoosT 2-690 with Paul Mermelstein (invite your friends)
More informationAdverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology
Adverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology Marcel Leist In Vitro Toxicology and Biomedicine Doerenkamp-Zbinden Chair, University of Konstanz, Germany
More informationAbstracts and affiliations
Dopamine Discovery Day August 30, 2012 Rikshospitalet Store auditorium, Oslo, Norway Organized by Linda H. Bergersen & Vidar Gundersen Institute of Basic Medical Sciences & Centre for Molecular Biology
More informationSmoking, nicotine and Parkinson s disease
Review TRENDS in Neurosciences Vol.27 No.9 September 2004 Smoking, nicotine and Parkinson s disease Maryka Quik The Parkinson s Institute, 1170 Morse Avenue, Sunnyvale, CA 94089, USA Epidemiological studies
More informationVisualization and simulated animations of pathology and symptoms of Parkinson s disease
Visualization and simulated animations of pathology and symptoms of Parkinson s disease Prof. Yifan HAN Email: bctycan@ust.hk 1. Introduction 2. Biochemistry of Parkinson s disease 3. Course Design 4.
More informationMalattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche
LA NEUROSONOLOGIA NELLE PATOLOGIE DEGENERATIVE E VASCOLARI CEREBRALI San Benedetto del Tronto 6-8 novembre 2017 Malattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche Giuseppe De Michele
More informationNovel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson s disease
Baranyi et al. Molecular Neurodegeneration (2016) 11:6 DOI 10.1186/s13024-015-0067-y RESEARCH ARTICLE Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson
More informationThis student paper was written as an assignment in the graduate course
77:222 Spring 2003 Free Radicals in Biology and Medicine Page 0 This student paper was written as an assignment in the graduate course Free Radicals in Biology and Medicine (77:222, Spring 2003) offered
More informationThe Nervous System Mark Stanford, Ph.D.
The Nervous System Functional Neuroanatomy and How Neurons Communicate Mark Stanford, Ph.D. Santa Clara Valley Health & Hospital System Addiction Medicine and Therapy Services The Nervous System In response
More informationAlterations of nocturnal activity in rats following subchronic oral administration of the neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro-b-carboline
J Neural Transm (2009) 116:1267 1271 DOI 10.1007/s00702-009-0261-6 MOVEMENT DISORDERS - ORIGINAL ARTICLE Alterations of nocturnal activity in rats following subchronic oral administration of the neurotoxin
More informationTeach-SHEET Basal Ganglia
Teach-SHEET Basal Ganglia Purves D, et al. Neuroscience, 5 th Ed., Sinauer Associates, 2012 Common organizational principles Basic Circuits or Loops: Motor loop concerned with learned movements (scaling
More informationTestosterone Replacement Attenuates Haloperidol-Induced Catalepsy in Male Rats
Advanced Pharmaceutical Bulletin, 2014, 4(3), 237-241 doi: http://dx.doi.org/10.5681/apb.2014.034 http://apb.tbzmed.ac.ir/ Testosterone Replacement Attenuates Haloperidol-Induced Catalepsy in Male Rats
More informationHomeostasis. Endocrine System Nervous System
Homeostasis Endocrine System Nervous System 2004-2005 Regulation Why are hormones needed? chemical messages from one body part to another communication needed to coordinate whole body homeostasis & regulation
More informationExam 2 PSYC Fall (2 points) Match a brain structure that is located closest to the following portions of the ventricular system
Exam 2 PSYC 2022 Fall 1998 (2 points) What 2 nuclei are collectively called the striatum? (2 points) Match a brain structure that is located closest to the following portions of the ventricular system
More informationCell Therapy in Parkinson s Disease
NeuroRx : The Journal of the American Society for Experimental NeuroTherapeutics Cell Therapy in Parkinson s Disease Olle Lindvall and Anders Björklund Wallenberg Neuroscience Center and Lund Strategic
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationNEURONS COMMUNICATE WITH OTHER CELLS AT SYNAPSES 34.3
NEURONS COMMUNICATE WITH OTHER CELLS AT SYNAPSES 34.3 NEURONS COMMUNICATE WITH OTHER CELLS AT SYNAPSES Neurons communicate with other neurons or target cells at synapses. Chemical synapse: a very narrow
More informationSullivan, Aideen M.; Toulouse, André. Article (peer-reviewed)
Title Author(s) Neurotrophic factors for the treatment of Parkinson's disease Sullivan, Aideen M.; Toulouse, André Publication date 2011-06 Original citation Type of publication Link to publisher's version
More informationTitle: Restorative Effects of Uridine Plus Docosahexaenoic Acid in a Rat Model of Parkinson's Disease
Elsevier Editorial System(tm) for Neuroscience Research Manuscript Draft Manuscript Number: NSR-D-08-00172R1 Title: Restorative Effects of Uridine Plus Docosahexaenoic Acid in a Rat Model of Parkinson's
More informationTHE EXPRESSION OF INOS IN MOUSE EXPERIMENTAL MODEL POINTS TO INFLAMMATORY CONDITIONS ASSOCIATED WITH PARKINSON S DISEASE
THE EXPRESSION OF INOS IN MOUSE EXPERIMENTAL MODEL POINTS TO INFLAMMATORY CONDITIONS ASSOCIATED WITH PARKINSON S DISEASE Fatima Laiche Noureddine Djebli Mostaganem University, Algeria Abstract Parkinson
More informationprocesses in the central nervous system (CNS), affecting many of the during the course of ethanol treatment. Ethanol stimulates the release of
INTRODUCTION INTRODUCTION Neuroscience research is essential for understanding the biological basis of ethanol-related brain alterations and for identifying the molecular targets for therapeutic compounds
More informationBMS 153: Neuroscience The chemical synapse + neurotransmitters- lectures Dr Pen Rashbass
BMS 153: Neuroscience The chemical synapse + neurotransmitters- lectures 12-14 Dr Pen Rashbass (p.rashbass@shef.ac.uk) THESE NOTES ARE MEANT TO BE SUPPLEMENTAL TO YOUR LECTURES/OWN READING THEY DO NOT
More informationBrain dopamine and mild hypoxia
Brain dopamine and mild hypoxia Denoroy L, Orset C, Parrot S, Berod A, Sauvinet V, Cottet-Emard JM, Pequignot JM. Université Claude Bernard, Lyon, France Striatum vulnerable to hypoxia ischemia necrotic
More informationNeurochemistry of psychiatric disorders. Dr. Radwan Banimustafa
Neurochemistry of psychiatric disorders Dr. Radwan Banimustafa Introduction Neurochemistry is the study of chemical interneuronal communication. Wilhelm and Santiago in the late 19 th century stated that
More informationMechanisms of L-DOPA-induced dyskinesia in Parkinson s Disease M. Angela Cenci
Mechanisms of L-DOPA-induced Dyskinesia in Parkinson s Disease 1 Prof., MD, PhD Professor of Experimental Medical Research Basal Ganglia Pathophysiology Unit Lund University, Lund (Sweden) Parkinson s
More informationEmbargoed until Oct. 18, 10:30 a.m. CDT Contacts: Kat Snodgrass, (202) Press Room, Oct : (312) Sarah Bates, (202)
Embargoed until Oct. 18, 10:30 a.m. CDT Contacts: Kat Snodgrass, (202) 962-4090 Press Room, Oct. 17 21: (312) 791-6619 Sarah Bates, (202) 962-4087 RUN FOR YOUR LIFE: NEW STUDIES SHOW BENEFITS OF EXERCISE
More informationCellular Neurobiology BIPN140
Cellular Neurobiology BIPN140 8 th (last) problem set will be on the class website this weekend; answers will be posted on Monday Review Session with Antonia & Susie: Monday Dec. 5 th 10:00-1:00 pm 3502
More informationParkinson's Disease. Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology
Parkinson's Disease Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology 18 February 2002 Parkinson Disease Neurological disease affecting over four million patients
More informationHYPERBARIC OXYGEN TREATMENT ON A PARKINSON S DISEASE PATIENT: A CASE STUDY Hoggard ML, Johnson KE and Shirachi DY. Chico Hyperbaric Center, Chico, CA
HYPERBARIC OXYGEN TREATMENT ON A PARKINSON S DISEASE PATIENT: A CASE STUDY Hoggard ML, Johnson KE and Shirachi DY. Chico Hyperbaric Center, Chico, CA 95926 and Department of Physiology and Pharmacology,
More informationImaging biomarkers for Parkinson s disease
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 6 MDS-ES/EAN: Neuroimaging in movement disorders - Level 2 Imaging biomarkers for Parkinson
More informationThe serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery.
The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery. Rylander, Daniella Published in: Parkinsonism & Related Disorders DOI: 10.1016/S1353-8020(11)70039-6 2012
More informationDopamine neuron systems in the brain: an update
Review TRENDS in Neurosciences Vol.30 No.5 Dopamine neuron systems in the brain: an update Anders Björklund 1 and Stephen B. Dunnett 2 1 Neurobiology Unit, Wallenberg Neuroscience Center, Department of
More informationVisualization and Quantification of the Striato pallidonigral Fibers in Parkinson's Disease Using Diffusion Tensor Imaging
Visualization and Quantification of the Striato pallidonigral Fibers in Parkinson's Disease Using Diffusion Tensor Imaging Yu Zhang, Katherine Wu, Shannon Buckley, Norbert Schuff On behalf of the Parkinson
More information05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century
Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000
More informationNeurochemistry. Dr. Radwan Banimustafa
Neurochemistry Dr. Radwan Banimustafa Introduction Neurochemistry is the study of chemical inter-neuronal communication. Wilhelm and Santiago in the late 19 th century stated that the brain consists of
More informationPortions from Chapter 6 CHAPTER 7. The Nervous System: Neurons and Synapses. Chapter 7 Outline. and Supporting Cells
CHAPTER 7 The Nervous System: Neurons and Synapses Chapter 7 Outline Neurons and Supporting Cells Activity in Axons The Synapse Acetylcholine as a Neurotransmitter Monoamines as Neurotransmitters Other
More informationPROPOSAL: Translational Safety Biomarker Assessment of Neurotoxicity
PROPOSAL: Translational Safety Biomarker Assessment of Neurotoxicity Andreas Jeromin, PhD Chief Scientific Officer NextGen Sciences DX Boston, MA Emerging Issues Session HESI Annual Meeting 12 June 2012
More informationThe role of FGF-9 expression in neuroprotection of melatonin and MPP + -induced parkinsonism model in vivo and in vitro Key words: FGF-9; melatonin;
-9 參 神 MPP + 神 : -9; ; MPP + ; 神 ; 狀 (FGFs)(FGFRs) 理 復 23 FGFs, FGF-2 FGF-9 神 :, 了 FGFs 年來 金, 神 神 (MPP + ) 神 IGFBDNFFGF-9 FGF 神 不 神 FGF-9 量 FGF-9 神 FGF-9 參 神 MPP + 狀 狀 FGF-9 mrna 量 狀 tyrosine hydroxylase
More informationThe Parkinson s You Can t See
The Parkinson s You Can t See We principally see the motor phenomena of Parkinson's disease, but is there an early stage without visible features? Might this provide a window for disease-modifying therapy?
More informationANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE
ANIMAL MODELS OF PARKINSON S DISEASE: STATE OF THE FIELD & THE FUTURE! KULDIP DAVE 21 February 217 MJFF IS THE WORLD S LARGEST NONPROFIT FUNDER OF PD RESEARCH Our Mission To accelerate the development
More informationA Parkinson s Disease and related disorders
A 3.5.2 Parkinson s Disease and related disorders 10 November 2016 Marinela Vavla marinela.vavla@kcl.ac.uk Learning objectives Basal ganglia: components and localization (inter)connections and functions
More informationStrategies for Neurorestoration: Growth Factors
Strategies for Neurorestoration: Growth Factors Elena Posse de Chaves, PhD 928-MSB Phone: 492-5966 Email: elena.chaves@ualberta.ca Treatment of Neurodegenerative Diseases Most neurodegenerative diseases
More informationCommunication Between
Communication Between Neurons Bởi: OpenStaxCollege The electrical changes taking place within a neuron, as described in the previous section, are similar to a light switch being turned on. A stimulus starts
More informationNa + /Cl - -dependent Neurotransmitter Transporters. Outline. Synaptic Transmission. How did the neurotransmitter cross the membrane?
Na /Cl - -dependent Neurotransmitter Transporters Stine Meinild Lundby The Neurobiology Group Molecular, Cellular, and Integrative Physiology Section November 26 th, 2007 slide 1 Outline Synaptic neurotransmission
More informationThe Marmoset Monkey as Model for Neurological Disorders
The Marmoset Monkey as Model for Neurological Disorders Jan Langermans and Ingrid Philippens From Laboratory to Clinic Disease models neuroscience: Parkinson, Sleep, Stress, Alzheimer, MS MS Models: rhmog
More informationProtective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons 1
Chen XC et al / Acta Pharmacol Sin 2002 Sep; 23 (9): 829-834 829 2002, Acta Pharmacologica Sinica ISSN 1671-4083 Shanghai Institute of Materia Medica Chinese Academy of Sciences http://www.chinaphar.com
More informationCOGS 269. Lecture 1 Spring 2018
COGS 269 Lecture 1 Spring 2018 Psychological Experience Methods of Cognitive Neuroscience Dissociation experiments (patients with brain damage) Neuroimaging experiments Computational modeling Brain damage
More informationThe fate of striatal dopaminergic neurons in Parkinson s disease and Huntington s chorea
doi:10.1093/brain/awl332 Brain (2007), 130, 222 232 The fate of striatal dopaminergic neurons in Parkinson s disease and Huntington s chorea Philippe Huot, 1,2 Martin Lévesque 1 and André Parent 1 1 Centre
More informationChapter 2. The Cellular and Molecular Basis of Cognition Cognitive Neuroscience: The Biology of the Mind, 2 nd Ed.,
Chapter 2. The Cellular and Molecular Basis of Cognition Cognitive Neuroscience: The Biology of the Mind, 2 nd Ed., M. S. Gazzaniga, R. B. Ivry, and G. R. Mangun, Norton, 2002. Summarized by B.-W. Ku,
More informationTITLE: Pharmacological and Behavioral Enhancement of Neuroplasticity in the MPTP- Lesioned Mouse and Nonhuman Primate.
AD Award Number: W81XWH-04-1-0444 TITLE: Pharmacological and Behavioral Enhancement of Neuroplasticity in the MPTP- Lesioned Mouse and Nonhuman Primate. PRINCIPAL INVESTIGATOR: Giselle M. Petzinger, M.D.
More informationReevaluation of levodopa therapy for the treatment of advanced Parkinson s disease
Parkinsonism and Related Disorders 15, Supplement 1 (2009) S25 S30 www.elsevier.com/locate/parkreldis Reevaluation of levodopa therapy for the treatment of advanced Parkinson s disease Masayuki Yokochi
More informationTITLE: Pharmacological and Behavioral Enhancement of Neuroplasticity in the MPTP- Lesioned Mouse and Nonhuman Primate
AD Award Number: W81XWH-04-1-0444 TITLE: Pharmacological and Behavioral Enhancement of Neuroplasticity in the MPTP- Lesioned Mouse and Nonhuman Primate PRINCIPAL INVESTIGATOR: Giselle Petzinger, M.D. Michael
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More informationI. OVERVIEW DIRECT. Drugs affecting the autonomic nervous system (ANS) are divided into two groups according to the type of
THE CHOLINERGIC NEURON 1 I. OVERVIEW DIRECT Drugs affecting the autonomic nervous system (ANS) are divided into two groups according to the type of ACTING neuron involved in their mechanism of action.
More informationParkinson Disease Treatment Research Pipeline Codrin Lungu MD Program Director, Office of Clinical Research Staff Clinician, Office of the Clinical
Parkinson Disease Treatment Research Pipeline Codrin Lungu MD Program Director, Office of Clinical Research Staff Clinician, Office of the Clinical Director NINDS, NIH Disclosures I receive payments from
More informationThe Pennsylvania State University The Graduate School College of Health and Human Development HOST SUSCEPTIBILITY TO ENVIRONMENTAL TOXICANTS
The Pennsylvania State University The Graduate School College of Health and Human Development HOST SUSCEPTIBILITY TO ENVIRONMENTAL TOXICANTS A Dissertation in Biobehavioral Health by Gelareh Alam 2015
More informationNERVOUS SYSTEM 1 CHAPTER 10 BIO 211: ANATOMY & PHYSIOLOGY I
BIO 211: ANATOMY & PHYSIOLOGY I 1 Ch 10 A Ch 10 B This set CHAPTER 10 NERVOUS SYSTEM 1 BASIC STRUCTURE and FUNCTION Dr. Lawrence G. Altman www.lawrencegaltman.com Some illustrations are courtesy of McGraw-Hill.
More informationReceived August 3, 2012; revised September 7, 2012; accepted September 21, 2012
Journal of Behavioral and Brain Science, 2012, 2, 485-494 http://dx.doi.org/10.4236/jbbs.2012.24057 Published Online November 2012 (http://www.scirp.org/journal/jbbs) Prenatal and Postnatal Exposures to
More informationSummarized by B.-W. Ku, E. S. Lee, and B.-T. Zhang Biointelligence Laboratory, Seoul National University.
Chapter 2. The Cellular l and Molecular Basis of Cognition Cognitive Neuroscience: The Biology of the Mind, 3 rd Ed., M. S. Gazzaniga, R. B. Ivry, and G. R. Mangun, Norton, 2008. Summarized by B.-W. Ku,
More informationCNB12 Plus. by ChiroNutraceutical. Recommended for:
CNB12 Plus by ChiroNutraceutical Recommended for: Increased Metabolism Nervous System Repair & Support Anti-Brain Aging Anemia Parkinson s, Alzheimer s and Multiple Sclerosis What is Methylcobalamin? Methylcobalamin
More informationSanneke van Vliet, Raymond Vanwersch, Marjan Jongsma, Jan van der Gugten, Berend Olivier, Ingrid Philippens
Neuroprotective effects of Δ 9 -tetrahydrocannabinol in a marmoset Parkinson model Sanneke van Vliet, Raymond Vanwersch, Marjan Jongsma, Jan van der Gugten, Berend Olivier, Ingrid Philippens Manuscript
More information- Neurotransmitters Of The Brain -
- Neurotransmitters Of The Brain - INTRODUCTION Synapsis: a specialized connection between two neurons that permits the transmission of signals in a one-way fashion (presynaptic postsynaptic). Types of
More informationNeuron types and Neurotransmitters
Neuron types and Neurotransmitters Faisal I. Mohammed. PhD, MD University of Jordan 1 Transmission of Receptor Information to the Brain the larger the nerve fiber diameter the faster the rate of transmission
More informationPHRM20001: Pharmacology - How Drugs Work!
PHRM20001: Pharmacology - How Drugs Work Drug: a chemical that affects physiological function in a specific way. Endogenous substances: hormones, neurotransmitters, antibodies, genes. Exogenous substances:
More informationMotor Fluctuations in Parkinson s Disease
Motor Fluctuations in Parkinson s Disease Saeed Bohlega, MD, FRCPC Senior Distinguished Consultant Department of Neurosciences King Faisal Specialist Hospital & Research Centre Outline Type of fluctuations
More informationUpdate on functional brain imaging in Movement Disorders
Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF
More informationAnalysis of Neurotransmitters. Simon Heales
Analysis of Neurotransmitters Simon Heales HealeS@gosh.nhs.uk Tyrosine O 2 L-Dopa Dopamine HVA Tryptophan 5-HTP PLP Serotonin 5-HIAA Phenylalanine Tyrosine BH4 qbh2 BH2 CSF Sample Requirements Tube 1 Tube
More informationbiological psychology, p. 40 The study of the nervous system, especially the brain. neuroscience, p. 40
biological psychology, p. 40 The specialized branch of psychology that studies the relationship between behavior and bodily processes and system; also called biopsychology or psychobiology. neuroscience,
More informationHuman Biology WACE 2016 Units 3 & 4
WACE Human Biology Year 2016 Mark 80.20 Pages 19 Published Jan 30, 2017 Human Biology WACE 2016 Units 3 & 4 By Sheryar (99.85 ATAR) Your notes author, Sheryar. Sheryar achieved an ATAR of 99.85 in 2016
More informationLecture Series Outline
Impact of vitamins & nutrients on neurological function Lecture Series Outline Week 1: Introduction to the brain Week 2: B-vitamins and development (Guest Lecture: Usha Shan) Week 3: B-vitamins and aging
More information